American Made Pharmaceuticals Act of 2022

Senate Bill 3991 - American Made Pharmaceuticals Act of 2022: Overview, Status, and Impact

Hozzl · 2022-12-29T23:48:39Z

Explore the details of Senate Bill 3991 American Made Pharmaceuticals Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 11:48 PM

Congressional Summary of S 3991

American Made Pharmaceuticals Act of 2022

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3991

Bill S 3991 is currently in the status of Bill Introduced since April 5, 2022. Bill S 3991 was introduced during Congress 117 and was introduced to the Senate on April 5, 2022. Bill S 3991's most recent activity was Read twice and referred to the Committee on Finance. as of April 5, 2022

Bipartisan Support of Bill S 3991

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3991

Primary Policy Focus

Health

Potential Impact Areas

- Buy American requirements

- Child health

- Congressional oversight

- Drug therapy

- Emergency medical services and trauma care

- Health care costs and insurance

- Health technology, devices, supplies

- Infectious and parasitic diseases

- Manufacturing

- Medicaid

- Medicare

- Poverty and welfare assistance

- Prescription drugs

- Public contracts and procurement

Alternate Title(s) of Bill S 3991

American Made Pharmaceuticals Act of 2022

A bill to direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.